PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2022 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.



Wednesday, August 17th

7:00 - 8:00 AM
INTRODUCTION TO A TREATMENT FOR ADULTS WITH ACUTE HEPATIC PORPHYRIA, INCLUDING ACUTE INTERMITTENT PORPHYRIA (SPONSORED BY ALNYLAM PHARMACEUTICALS)
Chicago Ballroom VI

Join Alnylam Pharmaceuticals for a presentation on a treatment for adults with acute hepatic porphyria (AHP) – including acute intermittent porphyria (AIP). AHP is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks. The cardinal symptom of an AHP attack is severe, diffuse abdominal pain. Presented by Dr. Ilene Weitz, this presentation will discuss a range of topics, including: • AHP disease overview and pathophysiology • Introduction to AHP treatment • Mechanism of Action • Efficacy and safety results from the Phase 3 Study and open-label extension Please join Alnylam Pharmaceuticals and Dr. Ilene Weitz, Professor of Clinical Medicine at the University of Southern California, to learn more about this treatment for adults with acute hepatic porphyria (AHP). Breakfast will be provided for attendees. This presentation is intended for US Healthcare Professionals only and no continuing education credits will be provided.


NOVEL INVESTIGATIONAL APPROACHES FOR HEMOPHILIA MANAGEMENT (SPONSORED BY SANOFI)
Chicago Ballroom IX-X

The symposium Novel Investigational Approaches for Hemophilia Management, organized by Sanofi, is intended for clinical and research experts in thrombosis, hemostasis, and vascular biology. Given the rapidly evolving therapeutic landscape in hemophilia management, there is a need for education on emerging treatments with novel mechanisms of action (MOA) and mechanisms of extension (MOE). The symposium will be presented in three parts: • Part 1 will provide a brief overview of current hemophilia management and unmet needs • Part 2 will describe the investigational molecule efanesoctocog alfa, with an MOE that overcomes the VWF-imposed half-life ceiling for FVIII replacement, and an overview of its clinical trial program • Part 3 will present the MOA of the investigational siRNA molecule fitusiran, and will conclude with an overview of its clinical trial program.

8:15 - 9:15 AM
BLEEDING: NOT OTHERWISE SPECIFIED (B-DUC)
Chair/Organizer: Yasmina Abajas, Maria Santaella
Sheraton Ballroom I-III

8:15
The Ideal Workup for Bleeding, NOS, and PE
Ming Lim. University of Utah

8:30
A Primer on Connective Tissue Disorders
Pamela Trapane. UF College of Medicine - Jacksonville

8:45
Pathophysiology of Bleeding in Connective Tissue Disorders
Rohith Jesudas. St. Jude Children's Research Hospital

9:00
Q&A
.
NOVEL TARGETS AND NOVEL USES FOR ANTICOAGULATION
Chair/Organizer: Vinai Bhagirath, Julie Jaffray
Sheraton Ballroom IV-V

8:15
Direct Factor XI Anticoagulant Trials Update
Noel Chan. McMaster University

8:30
Factor XI in Atherosclerosis
Owen McCarty. Oregon Health a Science University

8:45
Direct Oral Anticoagulants in Proteinuric Kidney Disease
Bryce Kerlin. Nationwide Children's / The Ohio State University College of Medicine

9:00
Q&A
.
QUALITY ASSURANCE IN THE HEMOSTASIS LABORATORY
Chair/Organizer: Katrien Devreese, Kristi Smock
Chicago Ballroom VII

8:15
Test Menu Updates for New Hemophilia Treatments
William Pickering. Labcorp Colorado Coagulation

8:30
Anti-Xa activity assays and Unfractionated Heparin Monitoring - Should this be the standard?
Karen Moser. University of Utah / ARUP Laboratories

8:45
Lessons Learned from Laboratory Practice in 2020
Morayama Gill. Cleveland Clinic

9:00
Q&A
.
9:15 - 10:00 AM
POSTERS/EXHIBITS/BREAK
Riverwalk AB
10:00 - 11:00 AM
SHORT TALKS - BLEEDING II
Chair/Organizer: Robert Sidonio, Yasmina Abajas
Sheraton Ballroom I-III

10:00
A library of siRNA lipid nanoparticles that knockdown specific pro- and anti-fibrinolytic proteins in animal models of thrombosis and bleeding.
Francesca Ferraresso1, Lih Jiin Juang1, Amy Strilchuk1, Christian Kastrup2, 3. 1Michael Smith Laboratories and Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada.2Blood Research Institute, Versiti, Milwaukee, WI, USA.3Departments of Surgery, Biochemistry, Biomedical Engineering, and Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA

10:12
Title: Mice with factor VIII deficiency show features of pain in hemophilia
Raghda Fouda1, Natalie Garcia1, Stacy Kiven 1, Kalpna Gupta1, 2. 1Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, CA, USA.2Southern California Institute for Research and Education, VA Medical Center, Long Beach, CA, USA

10:24
Proteostasis regulators improve protein secretion and activity of FVIII missense mutants.
Vishal Srivastava1, Wei Wei1, Zhigang Liu1, Zhang Yuan1, Tingwei Mu2, Zhang Bin1. 1Genomic Medicine Institute, Lerner Research Institute of Cleveland Clinic Cleveland, OH, USA.2Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH, USA

10:36
The frequency and significance of cross-reacting anti-porcine FVIII inhibitors in patients with congenital and acquired hemophilia A
Maddie S Stephen1, Carolyne Elbaz2, Hina Hanif3, Russell Ombao3, Jenny Gan3, Katerina Pavenski2, 3, Jerry Teitel2, Michelle Sholzberg2, 3. 1University of Toronto Department of Medicine, Toronto, ON, Canada.2Department of Medicine Division of Hematology/Oncology St. Michael's Hospital, Toronto, ON, Canada.3Department of Laboratory Medicine and Pathology, St. Michael's Hospital, Toronto, ON, Canada

10:48
Hereditary Hemorrhagic Telangiectasia is associated with a higher prevalence of heavy menstrual bleeding.
Kimberley/ M Youkhana1, Tamy/ H Moraes Tsujimoto2, Feng-Chang Lin2, Kristy Pahl3, Andra James 4, Nicole Schaefer5, Marianne/ S Clancy5, Raj/S Kasthuri1. 1University of North Carolina, Chapel Hill, Chapel Hill, NC, USA.2Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.33Division of Pediatric Hematology/Oncology, Duke University, Durham, NC, USA.4Department of Obstetrics and Gynecology, Duke University Durham, NC, USA.5Cure HHT Foundation, Monkton, MD, USA

SHORT TALKS - PLATELETS AND VESSELS
Chair/Organizer: Peter Kouides, Brett Grieb
Chicago Ballroom VII

10:00
Sickle red blood cell derived extracellular vesicles activate endothelial cells and enhance sickle red cell adhesion mediated by von Willebrand factor
Ran An1, Yuncheng Man1, Kevin Cheng1, Tianyi Zhang2, Chunsheng Chen3, Erdem Kucukal1, William Wulftange4, Utku Goreke1, Allison Bode1, 5, Lalitha Nayak5, Gregory Vercellotti3, John Belcher3, Jane Little6, Umut Gurkan1, 3, 7. 1Mechanical and Aerospace Engineering Department, Case Western Reserve University, Cleveland, OH, USA.2Physiology and Biophysics Department, Case Western Reserve University, Cleveland, OH, USA.3Division of Hematology, Oncology and Transplantation, Vascular Biology Center, University of Minnesota, Minneapolis, MN, USA.4Biomedical Engineering Department, Case Western Reserve University, Cleveland, OH, USA.5Department of Hematology and Oncology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.6Division of Hematology a UNC Blood Research Center, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.7Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA

10:12
Acquired platelet storage pool disorders in patients with hematologic malignancies
Brett Grieb, Rajiv K Pruthi, Dong Chen, Meera Sridharan. Mayo Clinic Rochester, Rochester, MN, USA

10:24
SARS-CoV-2 RBD and its variants can induce platelet activation and clearance: Implications for vaccinations and antibody therapy against COVID-19
Xiaoying Ma1, 2, Jady Liang2, 3, Guangheng Zhu2, 4, Preeti Bhoria2, 4, Daniel T MacKeigan2-5, Lisha Lin1, 2, Ziyan Chen1, 2, 4, 6, Zhenze Liu2, Chuanbin Shen1, 2, Yuchong Li2, 7, Hamed Shaykhalishahi2, 4, Jiamin Zhang1, 2, Pingguo Chen1, 2, Haibo Zhang2, 3, 5, 7, 8, Ori Rotstein2, 5, Heyu Ni1-6. 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.2Keenan Research Centre for Biomedical Science of St. Michael, Toronto, ON, Canada.3Department of Physiology, University of Toronto, Toronto, ON, Canada.4Toronto Platelet Immunobiology Group, Toronto, ON, Canada.5Department of Medicine, University of Toronto, Toronto, ON, Canada.6Canadian Blood Services, Ottawa, ON, Canada.7The State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.8Department of Anesthesiology and Pain Medicine and Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada

10:36
HMGB1 mediates increased P2Y12 localization at the platelet surface in sickle cell disease
Deirdre Nolfi-Donegan1, 3, Gowtham Annarapu3, Lisa Maurer1, Cheryl Hillery1, Sruti Shiva2, 3. 1Department of Pediatrics, Division of Hematology/Oncology, Children, PITTSBURGH, PA, USA.2Department of Pharmacology a Chemical Biology, University of Pittsburgh, PITTSBURGH, PA, USA.3Heart, Lung, Blood Vascular Medicine Institute, University of Pittsburgh, PITTSBURGH, PA, USA

10:48
Persevering endothelial cell activation and hypercoagulability after COVID-19 recovery. The prospective ROADMAP-postCOVID-19 study.
Patrick Van Dreden1, 4, Meletios A. Dimopoulos2, Aurelie Rousseau1, Ismail Elalamy3, Grigorios Gerotziafas3, 4. 1Clinical Research Stago, Gennevilliers, France.2University of Athens School of Medecine, Athens, Greece.3APHP Hopital Tenon, Paris, France.4INSERM U938, Paris, France

SHORT TALKS - THROMBOSIS CLINICAL AND SCIENCE
Chair/Organizer: Katrien Devreese, Shreya Agarwal
Sheraton Ballroom IV-V

10:00
Exploring the Risk Factors for Venous Thromboembolism in children with Sickle Cell Disease
Shreya Agarwal 1, 2, Kayla Foster 1, 2 , Shaniqua Johnson 1, 2 , Mary Shapiro 1, 2 , HyoJyeong Han1, 2 , Michael E. Scheurer 2, 3 , Gladstone Airewele 1, 2, Sarah E. Sartain 1, 2. 1Texas Children's Hospital, Division of Pediatric Hematology-Oncology, Houston, TX, USA.2Baylor College of Medicine, Houston, TX, USA.3Texas Children's Hospital, Center for Epidemiology and Population Health, Houston, TX, USA

10:12
Finding the Gap in Pediatric Post-Thrombotic Syndrome
Denise Bastas, Leonardo Brandao, Jennifer Vincelli, Nour Amiri, Karem Abdul-Samad, Samantha Stephens, Laura Avila . The Hospital for Sick Children, Toronto, ON, Canada

10:24
Characterizing a Physiologically Relevantin-vitroThrombolysis Model Utilizing Fluorescently Labeled Clots Formed Under Shear
Alexei Christodoulides1, Ziqian Zeng2, Nathan J Alves1, 2. 1Indiana University School of Medicine - Department of Emergency Medicine, Indianapolis, IN, USA.2Purdue University - Department of Biomedical Engineering, West Lafayette, IN, USA

10:36
In vivo murine studies demonstrate that neutrophil activation by anti-NAP2 antibodies contributes to vaccine-induced immune thrombocytopenia and thrombosis (VITT)
Conroy O Field1, 2, Hyunjun Kim1, M. Anna Kowalska1, 7, Matthew D Weitzman3, 4, Gowthami Arepally6, Douglas B Cines3, Lubica Rauova1, 5, Mortimer Poncz1, 5. 1Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.2Pharmacology Graduate Group, University of Pennsylvania, Philadelphia, PA, USA.3Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.4Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.5Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.6Division of Hematology, Duke University Medical Center, Durham, NC, USA.7Institute of Medical Biology, Polish Academy of Science, Lodz, Poland
11:05 - 12:20 PM
DIVERSITY, EQUITY, AND INCLUSION
Chair/Organizer: Cathy Hayward, Robert Sidonio
Sheraton Ballroom IV-V

INTRODUCTION VIDEO
.

11:05
Promoting equity and diversity in academic and clinical practice
Sonia Anand. McMaster University

11:25
Combating sexism in diagnosing and managing bleeding disorders
Angela Weyand. University of Michigan Medical School

11:45
Addressing barriers in patient care: a panel discussion
Sara Vazquez. University of Utah Health

12:05
Q&A
.
12:35 - 1:35 PM
GENE THERAPY ELIGIBILITY: DELINEATING DIFFERENCES FROM CLINICAL TRIAL TO CLINICAL PRACTICE (SPONSORED BY CSL BEHRING MEDICAL AFFAIRS)
Chicago Ballroom IX-X

Join us and engage in a robust dialogue covering clinical and psychosocial considerations for gene therapy. This panel discussion, led by speakers from multidisciplinary teams will address topics such as: 1) Determining patient eligibility, insights from clinical trial to apply to clinical practice 2) Addressing liver health considerations and evaluation for referrals to a partnering hepatologist 3) Assessing eligibility based on lifestyle screening, patient expectations and commitment of therapy MODERATOR: Michael Recht, MD, PhD, MBA is the Chief Science Officer, American Thrombosis and Hemostasis Network; Professor of Clinical Pediatrics at Yale University School of Medicine SPEAKER PANEL includes: Sabrina Farina, LMSW at UT Health Houston; Mark Reding, MD a Professor of Medicine & Center for Bleeding and Clotting Disorders Director at the University of Minnesota Medical Center and Bruce Luxon, MD, PhD who is a Chair of the Department of Medicine Chief of Service for the Department of Medicine at Georgetown University Hospital


PROPHYLAXIS IN PATIENTS WITH VON WILLEBRAND DISEASE: EXPERT PERSPECTIVES AND SHARED EXPERIENCES - (ORGANIZED BY MEDICOM WORLDWIDE, INC AND IS SUPPORTED BY AN EDUCATIONAL GRANT FROM TAKEDA PHARMACEUTICALS U.S.A., INC.)
Chair/Organizer: Robert Sidonio, Jr
Chicago Ballroom VI

We invite you to join us for a dynamic and interactive panel discussion focused on new advances in prophylaxis treatment for von Willebrand Disease (VWD) and data supporting emerging therapeutic strategies. Our panel will spend time addressing guidelines, treatment strategies, and patient management considerations. Come prepared with your questions for an engaging discussion.
Click Here to take the post survey.

1:50 - 3:20 PM
MANAGEMENT OF UNUSUAL SITE THROMBOSIS ACROSS THE AGE SPECTRUM
Chair/Organizer: Julie Jaffray, Anne Rose
Sheraton Ballroom IV-V

1:50
Splanchnic Vein Thrombosis
Anita Rajasekhar. University of Florida

2:15
Cerebral Sinus Venous Thrombosis (CSVT) Diagnosis and Treatment
Thalia Field. University of British Columbia

2:40
Shared Decision Making When There is Limited Evidence
Stephan Moll. University of North Carolina School of Medicine

3:05
Q&A
.
NEW THERAPIES FOR BLEEDING DISORDERS
Chair/Organizer: Robert Sidonio, Michael Recht
Sheraton Ballroom I-III

INTRODUCTION VIDEO
.

1:50
Emicizumab in the High Achieving Athlete
Meera Chitlur. Central Michigan University/Children's Hospital of Michigan

2:15
New Agents: biv-001 and Rebalancing Agents
Mark Reding. University of Minnesota

2:40
New Therapies for Bleeding Other Than Hemophilia
Ayesha Zia. University of Texas Southwestern, Dallas, TX

3:05
Q&A
.
PATHOGENESIS AND LABORATORY DIAGNOSIS OF PLATELET PROTHROMBOTIC STATES
Chair/Organizer: Cathy Hayward, Peter Kouides
Chicago Ballroom VII

1:50
Platelet Mechanics and Bleeding Phenotype
Oluwamayokun Oshinowo. Georgia Institute of Technology/Emory University

2:15
Pathogenesis of Platelet Prothrombotic States (HITT/VITT)
Donnie Arnold. McMaster University

2:40
Overview of Laboratory Diagnostic Testing Assays for HITT vs VITT
Anand Padmanabhan.

3:05
Q&A
.
3:20 - 4:05 PM
POSTERS/EXHIBITS/BREAK
Riverwalk AB
4:05 - 5:35 PM
HEALTH AND WELLNESS IN HEMOSTASIS AND THROMBOSIS
Chair/Organizer: Lena Volland, Michael Recht
Sheraton Ballroom I-III

INTRODUCTION VIDEO
.

4:05
The Psychological Impact of Pulmonary Embolism
Rachel Rosovsky. Massachusetts General Hospital and Harvard Medical School

4:30
The Psychological Impact of Pain in Hemophilia
Lena Volland. National Hemophilia Foundation

4:55
The Psychological Impact of Thrombosis in Athletes
Julie Partridge. Southern Illinois University Carbondale

5:20
Q&A
.
IMPROVING THROMBOPHILIA AND BLEEDING DISORDER INVESTIGATIONS
Chair/Organizer: Karen Moser, Marian Rollins-Raval
Chicago Ballroom VII

INTRODUCTION VIDEO
.

4:05
Contributions of Betsy VanCott to Thrombosis Laboratory Medicine
Catherine Hayward. McMaster University

4:30
Improving Diagnosis of Rare Bleeding Disorders
Rajiv Pruthi. Mayo Clinic

4:55
Top 5 visual design tips for teaching coagulation
Evelyn Lockhart. University of New Mexico Health Science Center

5:20
Q&A
.
NOVEL HEMOSTASIS MECHANISMS
Chair/Organizer: Meera Chitlur, Bhavya Doshi
Sheraton Ballroom IV-V

4:05
Novel Platelet Mimetics for Hemostasis
Anirban Sen Gupta. Case Western Reserve University

4:30
Hyperactive Gene Variants for Hemophilia Therapy
Ben Samelson-Jones. The Children's Hospital of Philadelphia

4:55
Breaking the fibrinolytic speed limit with magnetically powered microbots
Keith Neeves. University of Colorado Denver | Anschutz Medical Campus

5:20
Q&A
.
5:35 - 6:20 PM
POSTERS/EXHIBITS/BREAK
Riverwalk AB
6:20 - 7:35 PM
FOCUS ON FACTOR(SPONSORED BY SANOFI)
Chicago Ballroom IX-X

Treating hemophilia is often about balancing clinical needs with the lifestyle of each patient. Please join our upcoming symposium, Focus on Factor, at this year’s Thrombosis & Hemostasis Summit of North America (THSNA). During this time, Joanna Davis, MD and Guy Young, MD will share clinical data on treatment options of hemophilia A and hemophilia B. Q&A will follow the presentation.


IMMUNE THROMBOCYTOPENIA: EXPERT GUIDANCE TO INTEGRATE EMERGING THERAPIES INTO CLINICAL PRACTICE (SPONSORED BY CLINICAL CARE OPTIONS, LLC)
Chicago Ballroom VI

This 1.0-hour, CME-certified live satellite symposium will feature expert faculty presentations and discussions on integrating established and emerging therapies into the clinical management of immune thrombocytopenia (ITP). Topics that will be discussed will include treatment considerations for patients who are newly diagnosed with ITP, strategies for the optimal selection and sequencing of therapies for patients with progressing ITP, and the integration of novel and emerging therapies into the treatment of ITP. The faculty presentations and discussions also will feature expert guidance on the application of current clinical algorithms and evidence-based guidelines to the management of steroid-unresponsive ITP and considerations for treating ITP in special patient populations, such as children and those with chronic liver disease. These presentations will highlight key abstracts presented at THSNA 2022. Of importance, the faculty presenters will have the opportunity to engage in a lively panel discussion while answering pressing questions from the audience.